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Abstract 
The nitric oxide (NO) donor sodium nitroprusside (SNP) may promote cyanide-induced 
toxicity and systemic and/or local responses approaching maximal vasodilation. The hypotheses 
were tested that SNP superfusion of the rat spinotrapezius muscle exerts 1) residual impairments 
in resting and contracting blood flow, oxygen utilization ( 2OV ) and microvascular O2 pressure 
(PO2mv); and 2) marked hypotension and elevation in resting PO2mv. Two superfusion protocols 
were performed: 1) Krebs-Henseleit (control 1), SNP (300 µM; a dose used commonly in 
superfusion studies) and Krebs-Henseleit (control 2), in this order; 2) 300 and 1200 µM SNP in 
random order. Spinotrapezius muscle blood flow (radiolabeled microspheres), 2OV  (Fick 
calculation) and PO2mv (phosphorescence quenching) were determined at rest and during 
electrically-induced (1 Hz) contractions. There were no differences in spinotrapezius blood flow, 
2OV  or PO2mv at rest and during contractions pre- and post-SNP condition (control 1 and control 
2; p>0.05 for all). With regard to dosing, SNP produced a graded elevation in resting PO2mv 
(p<0.05) with a reduction in mean arterial pressure only at the higher concentration (p<0.05). 
Contrary to our hypothesis, skeletal muscle superfusion with the NO donor SNP (300 µM) 
improved microvascular oxygenation during the transition from rest to contractions (PO2mv 
kinetics) without precipitating residual impairment of muscle hemodynamic or metabolic control 
or compromising systemic hemodynamics. These data suggest that SNP superfusion (300 µM) 
constitutes a valid and important tool for assessing the functional roles of NO in resting and 
contracting skeletal muscle function without incurring residual alterations consistent with 
cyanide accumulation and poisoning. 
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Introduction 
 Nitric oxide (NO) and its derivatives are important modulators of skeletal muscle 
hemodynamic and metabolic control (Stamler and Meissner, 2001). During the transition from 
rest to contractions, NO contributes to the increase in skeletal muscle oxygen delivery ( 2OQ ) 
mainly via endothelium-dependent vasodilation (Hirai et al., 1994; Schrage et al., 2004) and the 
inertia of oxidative metabolism (i.e., finite 2OV  kinetics) via inhibition of mitochondrial 
respiration (Jones et al., 2003; Kindig et al., 2002). Accordingly, alterations in NO levels within 
skeletal muscle impact profoundly the dynamic 2OQ / 2OV  matching (and thus the O2 pressure 
within the microvasculature; PO2mv) during metabolic transitions in health and disease (Ferreira 
et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010). Pharmacological agents 
that release NO therefore represent valuable research tools for assessing the mechanistic roles of 
NO in physiology and pathophysiology (Ignarro et al., 2002). 
 The NO donor sodium nitroprusside (SNP; sodium pentacyanonitrosylferrate, 
Na2[Fe(CN)5(NO)]) is a potent vasodilator used widely in both clinical and research arenas 
(human and animal models; Friederich and Butterworth, 1995; Ignarro et al., 2002). SNP has 
rapid onset and reversibility of action and produces vasodilatory effects that resemble closely 
those of endogenous, endothelium-derived NO (Miller et al., 2004; Wanstall et al., 2001). 
However, because SNP metabolism releases cyanide and may promote oxidative stress, its usage 
carries the risk of toxicity with prolonged administration and/or high dosages (Friederich and 
Butterworth, 1995; Ignarro et al., 2002; Pettersen and Cohen, 1993; Rao et al., 1991; Rauhala et 
al., 1998). Specifically, cyanide-induced toxicity is associated with inhibition of mitochondrial 
oxidative phosphorylation (Pettersen and Cohen, 1993; Way, 1984) and impairments in 
vasomotor control (and consequently blood flow and/or mean arterial pressure regulation; 
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Ignarro et al., 1986) which are expected to result in 2OQ / 2OV  mismatch. These concerns led to 
reports recommending SNP usage to be curtailed or even discontinued (Rauhala et al., 1998; 
Robin and McCauley, 1992; Varon and Marik, 2003) and the Food and Drug Administration 
(FDA) approving a label for clinical SNP usage in 1991 that highlights its potential toxicity due 
to cyanide accumulation (Nightingale, 1991). 
 The purpose of the present investigation was to determine whether SNP superfusion 
disrupts the functional integrity of skeletal muscle hemodynamic and/or metabolic control at rest 
and during contractions. It was hypothesized that skeletal muscle superfusion with SNP (300 
µM, a concentration of the order employed in our and other laboratories; Behnke and Delp, 
2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et al., 2006b; 
Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Padilla et 
al., 2010; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009) would exert residual (i.e., post-
washout) impairment of skeletal muscle blood flow, 2OV  and PO2mv during the transition from 
rest to contractions and responses consistent with or approximating maximal vasodilation (i.e., a 
saturation dose accompanied by marked hypotension and elevation in resting PO2mv). 
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Methods 
A total of 27 male Sprague-Dawley rats (4-5 months old; Charles Rivers Laboratories, 
Boston, MA, USA) were utilized in the present investigation. All experimental procedures 
followed guidelines established by the National Institutes of Health and were approved by the 
Institutional Animal Care and Committee of Kansas State University. Rats were housed in 
accredited facilities and maintained on a 12:12 h light-dark cycle with food and water available 
ad libitum. 
 
Surgical procedures 
On the day of data collection, rats were anesthetized initially with a 5% isoflurane-O2 
mixture and maintained on 2-3% isoflurane-O2 (Butler Animal Health Supply, Dublin, OH, 
USA). The right carotid and caudal (tail) arteries were cannulated (PE-10 connected to PE-50; 
Intra-Medic Tubing, Clay Adams Brand, Sparks, MD, USA) for continuous measurements of 
mean arterial pressure (MAP; Digi-Med BPA model 200, Louisville, KY, USA), infusion of the 
phosphorescent probe palladium meso-tetra (4-carboxyphenyl) porphyrin dendrimer (R2; 15 
mg/kg; Oxygen Enterprises, Philadelphia, PA, USA) and arterial blood sampling. Blood samples 
were taken at the end of each experimental protocol for determination of arterial blood gases and 
systemic hematocrit (Nova Stat Profile M, Waltham, MA, USA). Anesthetized rats were kept on 
a heating pad to maintain core temperature at ~37-38°C (measured via rectal probe). 
 Following catheter placement procedures, rats were transitioned progressively to 
pentobarbital sodium (administered i.a. to effect) and monitored frequently via the toe-pinch and 
blink reflexes with anesthesia supplemented as necessary. Overlying skin and fascia were then 
reflected carefully from the mid-dorsal region of the rat to expose the left and right 
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spinotrapezius muscles. Stainless steel electrodes were sutured to the rostral (cathode) and caudal 
(anode) regions of the right spinotrapezius muscle for electrically-induced contractions. Exposed 
muscles were moistened frequently during the surgical preparation via superfusion of Krebs-
Henseleit bicarbonate-buffered solution (4.7 mM KCl, 2.0 mM CaCl2, 2.4 mM MgSO4, 131 mM 
NaCl and 22 mM NaHCO3; pH = 7.4; equilibrated with 5% CO2 and 95% N2 at ~38°C) whereas 
surrounding tissue was covered with Saran wrap (Dow Brands, Indianapolis, IN, USA). Previous 
reports from our laboratory demonstrate that these surgical procedures do not impair the 
microvascular integrity and responsiveness of the rat spinotrapezius muscle (Bailey et al., 2000). 
 
Experimental protocols 
 Rats were assigned randomly to different groups to examine whether the SNP 
superfusion concentration of the order employed in our and other laboratories (300 µM; Behnke 
and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et 
al., 2006b; Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; 
Padilla et al., 2010; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009) evokes residual 
impairments in skeletal muscle hemodynamic and/or metabolic function (Group A; n=15) or 
responses consistent with maximal vasodilation (Group B; n=12). Chemicals and drugs were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and concentrations were chosen based on 
previous investigations from our and other laboratories (Behnke and Delp, 2010; Boegehold, 
1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2012; 
Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Padilla et al., 2010; Saito et 
al., 1994; Sato et al., 2008; Trott et al., 2009). Specifically, the 300 µM SNP superfusion 
concentration was titrated to evoke consistent alterations in PO2mv without compromising 
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systemic hemodynamics (i.e., a decrease in MAP below 70 mmHg at any time; Behnke et al., 
2006; Ferreira et al., 2006b). All solutions were kept at ~38°C. In order to minimize SNP 
photodecomposition and potential cyanide release (Bisset et al., 1981; Butler et al., 1987), SNP 
solutions were protected from light sources by covering containers and syringes with aluminum 
foil and, as a mandate for PO2mv measurements using phosphorescence quenching, performing 
experiments in a darkened room. 
 
Group A. Three contraction bouts were performed to examine potential impairment of 
spinotrapezius muscle hemodynamic and metabolic function with the relevant SNP superfusion 
(300 µM; see Fig. 1). The left and right spinotrapezius muscles were superfused in the following 
order: control 1 (5 ml Krebs-Henseleit), SNP (5 ml of a 300 µM SNP solution), control 2 (5 ml 
Krebs-Henseleit). Muscles were superfused with each solution (average flow rate of ~1.5 
ml/min) for a total time of 3 min, followed by a 3 min incubation period (i.e., no superfusion) to 
allow resting MAP and muscle PO2mv to stabilize. Subsequently, electrical stimulation (1 Hz, ~7 
V, 2 ms pulse duration) of the right spinotrapezius muscle was evoked via a Grass stimulator 
(model s48, Quincy, MA, USA) for 3 min and an ~20 min recovery period was undertaken 
before the next condition was initiated (stimulation parameters held constant). This stimulation 
protocol evokes an ~4-5 fold increase in blood flow along with ~6-7 fold increase in metabolic 
rate (i.e., ~30% of maximum spinotrapezius 2OV ) above resting with either minor or no changes 
in blood pH consonant with moderate intensity exercise (current results and Behnke et al., 2002; 
Behnke et al., 2001). During the recovery period following the SNP condition, the left and right 
spinotrapezius muscles were superfused at an average flow rate of ~1.5 ml/min with Krebs-
Henseleit to washout SNP. This experimental design is deemed appropriate to examine potential 
 9
impairments in skeletal muscle hemodynamic and metabolic function following SNP superfusion 
given that the current washout procedure is not expected to reverse any effects of cyanide-
induced toxicity with SNP (Reade et al., 2012; Way, 1984). Spinotrapezius muscle PO2mv was 
measured at rest and throughout contractions during all superfusion conditions. Spinotrapezius 
muscle blood flow and 2OV  were determined at rest and during the contracting steady-state 
during the first and third superfusion conditions (i.e., control 1 and control 2) via radiolabeled 
microspheres and direct Fick calculation, respectively. In each condition, the non-stimulated left 
and stimulated right spinotrapezius muscles represented the resting and contracting blood flow 
and 2OV  measurements, respectively. Resting blood flow to individual muscles or muscle parts 
of the hindlimb, kidneys and organs of the splanchnic region were also measured before and after 
superfusion of the spinotrapezius muscle with 300 µM SNP (i.e., control 1 and control 2 
conditions, respectively). Preliminary investigations describing the effects of 300 µM SNP 
superfusion on spinotrapezius muscle blood flow, 2OV  and PO2mv have been reported 
previously (Hirai et al., 2012; n=4 for blood flow and 2OV  and n=9 for PO2mv). The current 
investigation provides a complete description of that work (i.e., analysis of PO2mv kinetics 
parameters; n=15) using a larger data set along with novel measurements (blood flow to 
individual muscles or muscle parts of the hindlimb, kidneys and organs of the splanchnic region; 
n=10) and experimental protocols (effects of distinct SNP superfusion concentrations on 
systemic (MAP) and local (spinotrapezius PO2mv) responses. Crucial for quality control herein, 
a recent report from our laboratory demonstrated that the spinotrapezius preparation exhibits 
reproducible PO2mv profiles from three contraction bouts each separated by ~30 min (i.e., 3 min 
off-transition, ~20 min recovery, 3 min superfusion, 3 min incubation) with no ordering effects 
(Hirai et al., 2012). 
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Group B. Two distinct superfusion protocols were performed to investigate whether the relevant 
SNP superfusion (300 µM) evokes responses consistent with or approximating maximal 
vasodilation (i.e., marked hypotension and elevation in resting PO2mv; see Fig. 1). The right 
spinotrapezius muscle was superfused in random order (5 ml of a 300 or 1200 µM SNP solution; 
average flow rate of ~1.5 ml/min) for a total time of 3 min, followed by a 3 min incubation 
period (i.e., no superfusion) to allow resting MAP and muscle PO2mv to stabilize. These 
variables were measured and recorded and, before the second condition was initiated, the muscle 
was superfused for ~20 min at an average flow rate of ~1.5 ml/min with Krebs-Henseleit to wash 
out SNP. At the end of each experiment, rats were euthanized with intra-arterial pentobarbital 
sodium overdose (~50 mg/kg). 
 
Measurement of blood flow 
 During blood flow measurements, the tail artery catheter was connected to a 1 ml syringe 
and blood withdrawal was initiated at a constant rate of 0.25 ml/min via a pump (model 907, 
Harvard Apparatus, Holliston, MA, USA). Differentially radiolabeled microspheres (57Co and 
85Sr, 15 µm diameter; Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) were 
injected in random order into the aortic arch via the carotid artery catheter during the contracting 
steady-state (i.e., ~3 min after the onset of muscle contractions). Upon completion of the 
experiment and immediately after euthanasia, the left and right spinotrapezius muscles, 
individual muscles or muscle parts of the hindlimb, kidneys and organs of the splanchnic region 
(adrenals, stomach, spleen, pancreas, small intestine, large intestine, liver) were dissected, 
removed and weighed. The thorax was opened and placement of the arterial catheter into the 
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aortic arch was confirmed. Tissue radioactivity was determined on a gamma scintillation counter 
(Packard Auto Gamma Spectrometer, Cobra model 5003, Downers Grove, IL, USA) and blood 
flow was determined by the reference method (Ishise et al., 1980) and expressed as ml/min/100 g 
tissue. Adequate mixing of the microspheres was verified for each injection by the demonstration 
of a <15% difference in blood flow between the left and right kidneys. 
 
Measurement of muscle PO2mv 
 Spinotrapezius PO2mv was measured by phosphorescence quenching using a Frequency 
Domain Phosphorometer (PMOD 5000; Oxygen Enterprises, Philadelphia, PA, USA). The 
principles of the phosphorescence quenching technique have been described in detail previously 
(Behnke et al., 2001). Briefly, this technique applies the Stern-Volmer relationship (Rumsey et 
al., 1988) which describes quantitatively the O2 dependence of phosphorescent probe (R2) via 
the following equation: 
 
)/(]1)/[(2   QkmvPO  
 
where Qk  is the quenching constant and   and   are the phosphorescence lifetimes in the 
absence of O2 and the ambient O2 concentration, respectively. The phosphor R2 (   = 601 µs 
and Qk  = 409 mmHg
-1.s-1 at pH = 7.4 and temperature ~38°C) (Lo et al., 1997) was infused ~15 
min prior to muscle contractions. The R2 probe binds to albumin and is distributed uniformly in 
the plasma, thus providing a signal corresponding to the volume-weighted O2 pressure in the 
microvascular compartment (primarily the PO2 within the capillaries, which volumetrically 
represents the major intramuscular space; Poole et al., 2004). The negative charge of the R2 
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probe also facilitates its restriction to the muscle intravascular space (Poole et al., 1995). The 
common end of the bifurcated light guide was placed 2-4 mm superficial to the dorsal surface of 
the exposed right spinotrapezius muscle. The phosphorometer modulates sinusoidal excitation 
frequencies between 100 Hz and 20 kHz and allows phosphorescence lifetime measurements 
from approximately 10 µs to 2.5 ms. The excitation light (524 nm; penetration depth of ~500 
µm) was focused on a randomly selected area of ~2 mm diameter of exposed muscle and PO2mv 
was recorded at 2 s intervals throughout the duration of the experimental protocol. 
 
PO2mv kinetics analysis 
 The kinetics of PO2mv during the onset of contractions were described by nonlinear 
regression analysis using the Marquardt-Levenberg algorithm (SigmaPlot 11.2; Systat software, 
San Jose, CA, USA). Transient PO2mv responses were fit with either a one- or two-component 
model (Behnke et al., 2001): 
 
One-component: 
)1( /)(2)(2)(2
TDt
BLt emvPOmvPOmvPO
  
 
Two-component: 
)1()1( 2/)2(221
/)1(
21)(2)(2
 TDtTDt
BLt emvPOemvPOmvPOmvPO
   
 
where PO2mv(t) is the PO2mv at a given time t, PO2mv(BL) corresponds to the pre-contracting 
resting PO2mv, Δ1 and Δ2 are the amplitudes for the first and second components, respectively, 
TD1 and TD2 are the independent time delays for each component, and τ1 and τ2 are the time 
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constants (i.e., time taken to achieve 63% of the response) for each component. Goodness of fit 
was determined using three criteria: 1) the coefficient of determination; 2) the sum of squared 
residuals; and 3) visual inspection. 
The mean response time (MRT; Macdonald et al., 1997) was used to describe the overall 
dynamics of the PO2mv fall: 
 
11  TDMRT  
 
where TD1 and τ1 are defined above. The MRT analysis was limited to the first component of the 
PO2mv response given that inclusion of an emergent second component underestimates the 
actual speed of PO2mv fall following the onset of contractions (Hirai et al., 2009). 
 The area under the PO2mv curve plotted as function of time (PO2Area; Hirai et al., 2010) 
was calculated throughout each 3 min contraction protocol to provide an index of the overall 
spinotrapezius muscle microvascular oxygenation (i.e., incorporating resting and contracting 
steady-state PO2mv, time delays, time constants and amplitudes of the response to yield a value 
expressed as mmHg.s). 
 
Calculation of muscle 2OV  
 Spinotrapezius 2OV  was estimated from PO2mv and blood flow measurements as 
described in detail previously (Hirai et al., 2012). Briefly, arterial O2 concentration (CaO2) was 
calculated from arterial blood samples whereas venous O2 concentration (CvO2) was calculated 
from the resting or contracting steady-state spinotrapezius PO2mv using the rat O2 dissociation 
curve (Hill coefficient of 2.6), the measured hemoglobin (Hb) concentration, a P50 of 38 mmHg, 
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and an O2 carrying capacity of 1.34 ml O2/g Hb (Altman and Dittmer, 1974). Resting and 
contracting steady-state spinotrapezius blood flow ( mQ ) values were then used to calculate 2OV  
using the Fick equation [i.e., )( 222 CvOCaOmQOV   ]. 
 
Statistical analyses 
 Data comparison was performed using paired and unpaired Student’s t-test or one-way 
repeated measures ANOVA where appropriate. Post hoc analyses were performed with the 
Student-Newman-Keuls test when a significant F ratio was detected. The level of significance 
was set at p<0.05. Results are presented as mean ± SE. 
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Results 
 Group A: Effects of 300 µM SNP superfusion on spinotrapezius vascular and metabolic 
function. Before and after washout of 300 µM SNP (i.e., control 1 and control 2, respectively), 
spinotrapezius muscle blood flow and 2OV  increased similarly from rest to contractions (p<0.05 
for all; Fig. 2). Importantly, there were no differences in these responses at rest and during 
contractions when comparing control 1 and post-washout control 2 (p>0.05 for all; Fig. 2). 
 SNP elevated resting and contracting steady-state PO2mv (PO2mv(BL) and PO2mv(SS), 
respectively; p<0.05 for both; Fig. 3 and Table 1). No differences in the amplitudes and time 
delays of the PO2mv response were observed among conditions (p>0.05 for all; Table 1). The 
speed of PO2mv fall at the onset of contractions (as assessed by the time constant for the primary 
component (τ1), mean response time (MRT), time to reach 63% of the primary amplitude (T63) 
and relative rate of PO2mv fall (Δ1PO2mv/τ1)) was markedly slowed in the SNP condition when 
compared to both control 1 and post-washout control 2 (p<0.05 for all; Table 1). As a result, 
SNP elevated the overall muscle microvascular oxygenation throughout contractions (PO2AREA) 
when compared to both control 1 and control 2 conditions (p<0.05; Table 1). Importantly, there 
were no differences in the PO2mv responses during the transition from rest to contractions when 
comparing control 1 and control 2 (p>0.05 for all kinetics parameters; Table 1). 
 There were no differences in total resting hindlimb muscle blood flow before and after 
superfusion of the spinotrapezius muscle with 300 µM SNP (control 1: 7 ± 1; control 2: 8 ± 1 
ml/min/100 g, respectively, p>0.05). Accordingly, 27 of 28 individual hindlimb muscles or 
muscle parts had similar blood flow when comparing control 1 and control 2 (exception: red 
gastrocnemius; Table 2). Similar blood flows to the kidneys and the majority of organs of the 
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splanchnic region (exception: pancreas; Table 3) were observed when comparing control 1 and 
control 2. 
Group B: Systemic and local effects of distinct SNP superfusion concentrations (300 and 
1200 µM). Pre-SNP superfusion MAP and spinotrapezius PO2mv were not different between 300 
and 1200 µM conditions (p>0.05 for both; Fig. 4). Spinotrapezius superfusion with 300 µM SNP 
did not reduce MAP (p>0.05) and elevated resting PO2mv by ~30% (p<0.05; Fig. 4). 
Spinotrapezius superfusion with 1200 µM reduced MAP by ~33% (p<0.05) and increased resting 
PO2mv to a greater extent (~88%) compared to the 300 µM SNP concentration (p<0.05; Fig. 4). 
Accordingly, the changes in MAP and resting PO2mv with 1200 µM SNP were greater than 
those observed with 300 µM SNP (p<0.05 for both; Fig. 4). 
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Discussion 
 Contrary to our principal hypothesis, the present investigation demonstrates that acute 
superfusion of the rat spinotrapezius with 300 µM SNP does not precipitate residual impairment 
of muscle hemodynamic or metabolic control either at rest or during contractions. Improved 
spinotrapezius muscle microvascular oxygenation during the rest-contraction transient (PO2mv 
kinetics) seen herein during the SNP bout (300 µM) is consistent with that reported previously 
(Ferreira et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010). Importantly, 
there were no differences in skeletal muscle blood flow, 2OV  or PO2mv responses at rest or 
during contractions prior to superfusion and following washout of SNP (300 µM). Moreover, 
muscle superfusion with 300 µM SNP did not decrease MAP and elevated resting PO2mv to a 
lesser extent when compared to a four times greater concentration (1200 µM SNP), suggesting 
that 300 µM SNP does not evoke responses consistent with or approximating maximal 
vasodilation (i.e., a ceiling effect). Such findings are indicative of preserved skeletal muscle 
function during transitions in metabolic demand following 300 µM SNP superfusion and 
inconsistent with vascular or metabolic (mitochondrial) poisoning associated with cyanide 
accumulation and toxicity. 
 
SNP and skeletal muscle function 
 SNP-induced toxicity is considered to arise primarily from cyanide release and 
accumulation as a product of its metabolism (Friederich and Butterworth, 1995; Ignarro et al., 
2002; Pettersen and Cohen, 1993; Rao et al., 1991). Cyanide inhibits mitochondrial oxidative 
phosphorylation and is thus expected to lower both resting and contracting muscle 2OV  
(Pettersen and Cohen, 1993). In addition, cyanide accumulation may rapidly and irreversibly 
 18
impair vasomotor control and consequently alter resting and contracting muscle blood flow 
(Ignarro et al., 1986). Consistent with these notions, cyanide poisoning is often used 
experimentally to inhibit mitochondrial respiration at cytochrome c oxidase (i.e., uncoupling 
agent; Shen et al., 1995; Shiva et al., 2007) and abolish vascular smooth muscle tone (e.g., Levy 
et al., 1993; Marano et al., 1999). These alterations, alone or in combination, are expected to 
disrupt the dynamic matching between muscle blood flow and 2OV  (and thus PO2mv) 
particularly during the rest-contraction transient. However, unchanged muscle blood flow and 
2OV  at rest and during contractions after superfusion of the spinotrapezius with 300 µM SNP 
and subsequent washout (i.e., control 1 and control 2, respectively; Fig. 2) suggests preserved 
muscle vascular and mitochondrial function post-SNP washout. The possibility of prolonged 
and/or irreversible vasodilation secondary to SNP-induced toxicity (Ignarro et al., 1986) is not 
supported based on the lack of differences in resting and contracting muscle blood flow between 
the first and third bouts (i.e., control 1 and control 2, respectively; Fig. 2). In addition, similar 
spinotrapezius PO2mv kinetics parameters and temporal profiles during the first and third bouts 
(i.e., control 1 and control 2, respectively; Table 1 and Fig. 3) are consistent with the notion that 
muscle vascular and mitochondrial function were not impaired following SNP washout. 
 Similar resting blood flows to the total hindlimb musculature and vast majority (27 of 28) 
of individual muscles or muscle parts of the hindlimb during the first and third bouts (i.e., control 
1 and control 2, respectively; Table 2) provide further evidence that superfusion of the 
spinotrapezius with 300 µM SNP did not induce systemic toxicity. This notion is also supported 
by the finding of similar blood flows to the kidneys and most organs of the splanchnic region 
when comparing control 1 and control 2 (the pancreas being the only exception; Table 3). 
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 Taken together, these data suggest that superfusion of the spinotrapezius with 300 µM 
SNP does not impair skeletal muscle hemodynamic and metabolic function at rest or during 
contractions. The apparent absence of local and systemic toxicity with the 300 µM SNP 
superfusion concentration observed herein occurred despite whatever cyanide radicals may have 
been released as a product of SNP metabolism (Friederich and Butterworth, 1995; Ignarro et al., 
2002; Rao et al., 1991; Rauhala et al., 1998). As reviewed previously (Friederich and 
Butterworth, 1995; Way, 1984), cyanide from SNP reacts mainly with methemoglobin to 
produce cyanomethemoglobin (which is in dynamic equilibrium with cyanide and nontoxic) or 
thiosulfate in the liver via the catalytic action of rhodanase to produce thiocyanate (which is 
excreted by the kidneys). Additional pathways of cyanide detoxification include reactions with 
cystine (Wood and Cooley, 1956) and those catalyzed by the enzyme mercaptopyruvate 
sulfurtransferase (Nagahara et al., 1999), among others. Toxicity is therefore expected to occur 
principally: 1) with prolonged administration and/or high dosages of SNP which promote 
cyanide accumulation; and/or 2) in patients with some degree of renal and/or hepatic 
insufficiency (Friederich and Butterworth, 1995; Ignarro et al., 2002). It might be anticipated that 
oxidative stress mediated by SNP occurs primarily under the former circumstances. Interestingly, 
the SNP label introduced by the FDA in 1991 is consistent with those notions and emphasizes 
the risk of cyanide toxicity due to inappropriate dosages and/or extended use (Nightingale, 
1991). It is important to note that the characteristics of the drug delivery method applied herein 
limit the potential toxic effects of cyanide accumulation from superfused SNP (see below). 
It must also be acknowledged that 1) certain methods used for assaying blood cyanide 
concentration; and/or 2) SNP photodecomposition (which facilitates cyanide release) may 
overestimate the role of cyanide-induced toxicity with SNP and have promulgated the notion of 
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SNP toxicity (Bisset et al., 1981; Butler et al., 1987). These aspects must be considered when 
utilizing the NO donor SNP in both clinical and research settings and may account, at least in 
part, for the controversy regarding SNP safety and reliability (Friederich and Butterworth, 1995). 
Thus, the lack of residual impairments in skeletal muscle function following SNP treatment 
demonstrated herein (Figs. 2 and 3) is consistent with the fact that appropriate administration of 
the NO donor SNP intravenously represents a powerful tool in the standard drug treatment of 
hypertension and chronic heart failure without promoting vascular and/or metabolic dysfunction 
(Cohn et al., 2011; Dickstein et al., 2008; Friederich and Butterworth, 1995; Ignarro et al., 2002). 
 It may be argued that other NO donors, such as diazeniumdiolates (e.g., spermine 
NONOate), could be used in an attempt to circumvent potential SNP-induced toxicity. However, 
heterogeneities in vasodilatory properties of NO donors must be taken into account based on the 
purpose of a given investigation. Contrary to SNP, spermine NONOate releases NO 
extracellularly and induces vasodilation via a soluble guanylate cyclase-independent mechanism, 
which differs from that associated with endogenous, endothelium-derived NO (Miller et al., 
2004; Wanstall et al., 2001). 
 
SNP superfusion concentrations 
 As noted above, the SNP superfusion concentration used herein (300 µM) is similar to 
that used by others (Behnke and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Lash 
and Bohlen, 1997; Muller-Delp et al., 2002; Padilla et al., 2010; Saito et al., 1994; Sato et al., 
2008; Trott et al., 2009) and was established in previous investigations by titrating different 
doses and selecting carefully that one which elicited consistent alterations in muscle PO2mv 
without compromising systemic hemodynamics (i.e., MAP<70 mmHg at any time; Behnke et al., 
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2006; Ferreira et al., 2006b). The 300 µM SNP concentration is therefore relatively higher than 
that used in intra-arterial infusions or isolated tissue incubation baths due to the nature of the 
drug delivery method (i.e., superfusion), in which 1) considerable resistance to diffusion exists 
inherently; and 2) superfused chemicals are only briefly in contact with the curved dorsum of the 
in situ spinotrapezius as gravity directs the fluid away from the muscle to be discarded. 
Importantly, spinotrapezius superfusion with 300 µM SNP did not decrease MAP and elevated 
resting PO2mv to a lesser extent when compared to 1200 µM SNP (Fig. 4). These data indicate 
that superfusion of the rat spinotrapezius muscle with 300 µM SNP increases resting PO2mv 
without evoking responses consistent with or approximating maximal vasodilation. The latter 
point is significant because it allows further vasodilation in response to muscle contractions or 
other mediators and does not abolish sympathetic neural control over vascular tone. As discussed 
previously (Ferreira et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2010), the very mild 
hypotensive response seen herein following SNP superfusion of the spinotrapezius muscle likely 
derives from ‘leakage’ of the superfusate from within the vicinity of the muscle into the systemic 
circulation. 
 
Experimental considerations 
 Technical limitations related to the presence of radiolabeled microspheres precluded 
direct cyanide measurements in resting and contracting skeletal muscle. In addition, blood 
samples were not taken for cyanide measurements given that the superfusion method used 
herein, contrary to SNP infusion, is not expected to impact systemic cyanide levels appreciably. 
Nonetheless, considering that SNP metabolism releases cyanide along with NO (Friederich and 
Butterworth, 1995), one strength of the current investigation is evaluation of potential adverse 
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effects of local SNP superfusion (300 µM) on resting and contracting skeletal muscle vascular 
and metabolic function in vivo (Group A). 
 Notwithstanding the synergistic and redundant nature of the multiple mechanisms 
regulating skeletal muscle blood flow, NO has been identified as an important component of the 
functional hyperemia response (e.g., Hirai et al., 1994; Schrage et al., 2004). That NO is integral 
to skeletal muscle 2OQ / 2OV  matching in health (Ferreira et al., 2006b; Hirai et al., 2010), aged 
(Hirai et al., 2009), disease (Ferreira et al., 2006a) and exercise trained (Hirai et al., 2012) states 
indicates that NO-mediated vascular and metabolic regulation in the rat spinotrapezius 
preparation is similar to those observed in the intact rat (Hirai et al., 1994), horse (Kindig et al., 
2002) and human (Jones et al., 2003; Schrage et al., 2004). 
 
Summary and conclusions 
 Utilization of NO donors such as SNP is pivotal in identifying the functional roles of NO 
in physiology and pathophysiology (Ignarro et al., 2002). The current investigation demonstrates 
that superfusion of the rat spinotrapezius with 300 µM SNP does not impair skeletal muscle 
hemodynamic or metabolic function at rest or during contractions. Importantly, this SNP 
superfusion concentration elevates resting muscle PO2mv without compromising systemic 
hemodynamics (i.e., MAP<70 mmHg at any time; present results and Behnke et al., 2006; 
Ferreira et al., 2006b) or altering resting blood flow to the total hindlimb musculature. In 
addition, no differences in basal blood flow to the kidneys and majority of the organs of the 
splanchnic region were observed when comparing pre- and post-SNP conditions. Collectively, 
these observations indicate that SNP superfusion (300 µM) constitutes a valid and important tool 
for assessing the functional roles of NO in skeletal muscle hemodynamic and metabolic control 
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at rest and during contractions without incurring residual alterations consistent with cyanide 
accumulation and poisoning. 
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Tables 
 
Table 1. Spinotrapezius muscle PO2mv kinetics following the onset of contractions under three 
superfusion conditions performed in the following order: control 1 (Krebs-Henseleit), SNP (300 
µM), control 2 (Krebs-Henseleit) 
 Control 1 SNP Control 2 
PO2mv(BL), mmHg 30.8 ± 1.6 42.8 ± 3.2* 29.0 ± 2.5 
Δ1PO2mv, mmHg 11.1 ± 1.1 11.9 ± 2.5 11.2 ± 1.7 
Δ2PO2mv, mmHg 3.9 ± 0.5  3.3 ± 0.6 
ΔTotalPO2mv, mmHg 9.0 ± 1.2 11.9 ± 2.5 9.9 ± 1.7 
PO2mv(SS), mmHg 21.8 ± 1.2 30.9 ± 1.9* 19.5 ± 1.4 
TD1, s 9.1 ± 1.3 4.9 ± 1.3 8.4 ± 1.5 
TD2, s 45.6 ± 12.9  47.4 ± 10.8 
τ1, s 14.9 ± 4.2 29.5 ± 5.8* 15.0 ± 3.3 
τ2, s 59.7 ± 7.3  49.7 ± 7.9 
MRT, s 23.4 ± 4.0 33.6 ± 5.7* 23.4 ± 4.0 
T63, s 19.8 ± 3.2 35.1 ± 7.9* 20.6 ± 2.9 
Δ1PO2mv/τ1, mmHg/s 1.4 ± 0.3 0.6 ± 0.2* 1.1 ± 0.2 
PO2Area, mmHg.s 4029 ± 203 5669 ± 358* 3696 ± 245 
Values are mean ± SE. PO2mv(BL), pre-contracting PO2mv; Δ1PO2mv, amplitude of the first 
component; Δ2PO2mv, amplitude of the second component; ΔTotalPO2mv, overall amplitude 
regardless of one- or two-component model fit; PO2mv(SS), contracting steady-state PO2mv; TD1, 
time delay for the first component; TD2, time delay for the second component; τ1, time constant 
for the first component; τ2, time constant for the second component; MRT, mean response time; 
T63, time to reach 63% of the primary amplitude as determined independent of modeling 
procedures; Δ1PO2mv/τ1, relative rate of PO2mv fall; PO2Area, area under the PO2mv curve over 
the 3 min contraction period. While the two-component exponential model was required to 
analyze the PO2mv kinetics in the control conditions in some instances (6 and 8 out of 15 profiles 
for control 1 and control 2, respectively), the one-component model was used to fit the SNP 
response in all cases. * p<0.05 vs. control 1 and control 2. 
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Table 2. Resting blood flow (ml/min/100g) to individual muscles or muscle parts of the hindlimb 
before and after superfusion of the spinotrapezius muscle with 300 µM SNP (i.e., control 1 and 
control 2; respectively) 
 Control 1 Control 2 
Ankle extensors   
Soleus 15 ± 1 14 ± 2 
Plantaris 8 ± 1 9 ± 2 
Gastrocnemius, red 8 ± 2 12 ± 3* 
Gastrocnemius, white 8 ± 2 7 ± 1 
Gastrocnemius, mixed 8 ± 1 8 ± 1 
Tibialis posterior 11 ± 4 14 ± 3 
Flexor digitorum longus 7 ± 4 17 ± 5 
Flexor halicus longus 7 ± 1 8 ± 1 
   
Ankle flexors   
Tibialis anterior, red 8 ± 3 10 ± 1 
Tibialis anterior, white 9 ± 2 9 ± 2 
Extensor digitorum longus 9 ± 2 7 ± 1 
Peroneals 13 ± 4 11 ± 3 
   
Knee extensors   
Vastus intermedius 12 ± 2 12 ± 2 
Vastus medialis 5 ± 1 6 ± 1 
Vastus lateralis, red 10 ± 2 12 ± 1 
Vastus lateralis, white 7 ± 1 9 ± 2 
Vastus lateralis, mixed 7 ± 1 7 ± 1 
Rectus femoris, red 6 ± 1 8 ± 1 
Rectus femoris, white 8 ± 1 8 ± 1 
   
Knee flexors   
Biceps femoris anterior 6 ± 1 5 ± 1 
Biceps femoris posterior 7 ± 1 8 ± 1 
Semitendinosus 6 ± 1 8 ± 1 
Semimembranosus, red 6 ± 1 8 ± 1 
Semimembranosus, white 7 ± 1 9 ± 1 
   
Thigh adductors   
Adductor longus 13 ± 3 10 ± 3 
Adductor magnus & brevis 6 ± 1 6 ± 1 
Gracilis 7 ± 1 8 ± 1 
Pectineus 6 ± 1 7 ± 1 
Values are mean ± SE. *p<0.05 vs. control 1. 
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Table 3. Blood flow (ml/min/100g) to the kidneys and organs of the splanchnic region before and 
after superfusion of the spinotrapezius muscle with 300 µM SNP (i.e., control 1 and control 2; 
respectively) 
 Control 1 Control 2 
Kidneys 480 ± 42 433 ± 62 
Adrenals 517 ± 63 614 ± 101 
Stomach 81 ± 16 50 ± 6 
Spleen 166 ± 21 190 ± 44 
Pancreas 113 ± 19 61 ± 14* 
Small intestine 295 ± 27 277 ± 16 
Large intestine 129 ± 14 105 ± 6 
Liver† 31 ± 10 34 ± 4 
Values are mean ± SE. *p<0.05 vs. control 1. †Designates arterial, not portal, blood flow and 
vascular conductance. 
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Figure legends 
 
Fig. 1 Schematic representation of the experimental protocol (diagram not to scale). Group A: 
Control 1 (Krebs-Henseleit), SNP (300 µM SNP), Control 2 (Krebs-Henseleit). Group B: 300 or 
1200 µM SNP superfusion in random order. S, superfusion (3 min); I, incubation (3 min); Stim, 
electrical stimulation of the right spinotrapezius muscle (3 min); R, recovery and washout (~20 
min). See text for further details. 
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Fig. 2 Spinotrapezius muscle blood flow (top panel) and 2OV  (bottom panel) at rest and during 
the contraction steady-state before and after superfusion with 300 µM SNP (i.e., control 1 and 
control 2, respectively). Three contraction bouts were performed in the following order: control 
1(Krebs-Henseleit), SNP (300 µM), control 2 (Krebs-Henseleit). Note similar spinotrapezius 
muscle blood flow and 2OV  responses between control 1 and control 2 both at rest and during 
the contraction steady-state (p>0.05 for all). n.s., not significantly different; *p<0.05 vs. rest. 
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Fig. 3 Top panel depicts the spinotrapezius muscle PO2mv at rest and during the onset of 
contractions under distinct superfusion conditions performed in the following order: control 1 
(Krebs-Henseleit), SNP (300 µM), control 2 (Krebs-Henseleit). Bottom panel further illustrates 
the change in muscle PO2mv with 300 µM SNP (elevated resting and contracting steady-state 
PO2mv along with slower speed of PO2mv fall at contractions onset, see Table 1) and the 
similarity between control 1 and control 2 (p>0.05 for all kinetics parameters, see Table 1). Time 
zero denotes the onset of muscle contractions. See text for further details. 
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Fig. 4 Effects of distinct SNP superfusion concentrations (300 and 1200 µM) on resting MAP 
(top panel) and spinotrapezius muscle PO2mv (bottom panel). Note that a four times greater 
concentration of SNP (1200 µM) evoked greater effects on both resting MAP and PO2mv when 
compared to the SNP concentration used currently in our and other laboratories (Behnke and 
Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et al., 
2006b; Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; 
Padilla et al., 2010; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009). Pre, pre-superfusion; 
post, post-superfusion; delta, difference between pre- and post-superfusion. *p<0.05 vs. pre-
superfusion within SNP concentration. †p<0.05 vs. 300 µM SNP within condition. 
